Pharmacology of Acetylcholinesterase Inhibitors and N‐methyl‐d‐aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The search for effective treatments of Alzheimer's disease (AD) is one of the major challenges facing modern medicine. Acetylcholinesterase (AChE) inhibitors (AChEIs) are effective for the treatment of mild to moderate AD, and memantine, an N‐methyl‐d‐aspartate ((NMDA) inhibitor, has been approved for moderate to severe AD. Galantamine is of particular interest because it has a dual mechanism of action: it is postulated to be both an AChEI and an allosteric modulator of nicotinic receptors. Modulation of NMDA and nicotinic receptors by memantine and galantamine may provide an optimal combination therapy for AD. The cholinergic and glutamatergic neurotransmitter systems, which share a close functional relationship, may play a role in the pathogenesis of AD. Close examination of the pharmacology of the 2 compounds suggests that galantamine can augment memantine's glutamatergic noise suppression while simultaneously enhancing the physiologic glutamatergic signal. The link between these systems suggests that AD therapies, which capitalize on this relationship, may be more effective in improving cognition than approaches focusing on a single system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“As originally proposed, the cholinergic hypothesis of AD states that the loss of cholinergic function in the central nervous system (CNS) contributes significantly to the cognitive decline associated with AD.(10,12,13) In advanced AD, severe loss of cholinergic cells in the nucleus basilis affects cholinergic innervat…”
BackgroundAlzheimer Disease in the US Population: Prevalence Estimates Using the 2000 Census
Hebert, L. E., Scherr, P. A., Bienias, J. L., Bennett, D. A., & Evans, D. A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1119 · Cited by 2,168 · cited 2×
“As the population ages, the prevalence of AD is expected to increase almost 3-fold by 2050, with an estimated 25 million people affected worldwide.(3)”
BackgroundMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159 · cited 2×
“Currently, the neurotransmitter systems most studied in the pathogenesis of AD are the cholinergic and glutamatergic systems.(4,10)”
BackgroundNicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070 · cited 3×
“Many reports have shown that activation of α7 nicotinic receptors located on presynaptic glutamatergic neurons stimulates glutamate release and increases the NMDA receptor activity on postsynaptic neurons.(23,43,44) A study using cultured rat hippocampal neurons showed that activation of presynaptic α7 nicotinic acety…”
BackgroundGlutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
Jackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Oddo, S., Caccamo, A., Green, K. N., Liang, K., Tran, L., Chen, Y., Leslie, F. M., & LaFerla, F. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408500102 · Cited by 211 · cited 1×
“A recent study reported that oral nicotine administration up-regulated nicotine receptors and increased τ phosphorylation in a transgenic mouse model of AD compared with age-matched controls.(14) In this model, β-amyloid pathology was not affected in this study.”
ResultDecreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1 H-MRS at 0.5 T
Antuono, P. G., Jones, J. L., Wang, Y., & Li, S.-J. (2001) · Neurology · doi:10.1212/wnl.56.6.737 · Cited by 119
Cited by
Molecular Pathogenesis of Alzheimer's Disease: An Update
Sanabria-Castro, A., Alvarado-Echeverría, I., & Monge-Bonilla, C. (2017) · Annals of Neurosciences · doi:10.1159/000464422 · Cited by 418
Calcium Signaling and Amyloid Toxicity in Alzheimer Disease
Demuro, A., Parker, I., & Stutzmann, G. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.080895 · Cited by 407
Simoni, E., Daniele, S., Bottegoni, G., Pizzirani, D., Trincavelli, M. L., Goldoni, L., Tarozzo, G., Reggiani, A., Martini, C., Piomelli, D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3009458 · Cited by 163
Uddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86
“accountable for the potentiation found in AD clinical trials with the combinations of memantine and AChEI has been investigated at various levels [92].”
BackgroundPerspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Metadata
- Authors
- Geerts, H., & Grossberg, G. T.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2006-07
- Volume
- 46
- Issue
- S1
- Pages
- 8S-16S
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1978581754
- Cited by
- 84
- References
- 10
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacology of Acetylcholinesterase Inhibitors and N‐methyl‐d‐aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. https://app.cochat.ai/papers/10.1177/0091270006288734
- The paper
- Geerts, H., & Grossberg, G. T. (2006). Pharmacology of Acetylcholinesterase Inhibitors and N‐methyl‐d‐aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270006288734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.